| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 01/23/2003 | WO2002046138A3 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 01/23/2003 | WO2002044086A3 Sodium zirconium carbonate and zirconium basic carbonate and methods of making the same |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002013798A3 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 01/23/2003 | WO2002010405A3 A human disintegrin protein |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2002008177A2 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/23/2003 | WO2002002607A3 Acid-modified arabinogalactan protein composition |
| 01/23/2003 | US20030018357 Wound closure system and methods |
| 01/23/2003 | US20030018193 Beta-alanine derivatives and their use as receptor anatgonists |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018075 Threonine, or mixture with methionine; side effect reduction |
| 01/23/2003 | US20030018072 Utilization of dialkylfumarates |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018064 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 01/23/2003 | US20030018058 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018026 Preterm labor; urogenital disorders; fertility; psychological disorders |
| 01/23/2003 | US20030018013 Cardiovascular disorders; antilipemic agents; Alzheimer's disease |
| 01/23/2003 | US20030017992 Crystalline forms |
| 01/23/2003 | US20030017546 Analogues of Kunitz protease inhibitor domain of amyloid precursor protein bind to and inhibit activity of serine proteases including kallikrein, plasmin, and coagulation factors VIIa, IXa, Xa, XIa, and XIIa; for treating blood loss |
| 01/23/2003 | US20030017188 Administered between 15 and 90 minutes prior to exposure of the subject to thrombogenic stimuli |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017147 Novel alpha-2-antiplasmin- binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient |
| 01/23/2003 | US20030017141 Treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject; isolating a stromal-cell-derived fugetactic agent |
| 01/23/2003 | CA2453309A1 Peptide for regulation of tissue plasminogen activator |
| 01/23/2003 | CA2453285A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | CA2453187A1 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2453147A1 Methods of treating cytokine mediated diseases |
| 01/23/2003 | CA2452391A1 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors |
| 01/23/2003 | CA2418173A1 N-substituted-1-amino-1,1-dialkylcarboxylic acid derivatives |
| 01/22/2003 | EP1277729A1 Ppar (gamma) modulators |
| 01/22/2003 | EP1276893A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276770A1 Proteins with a high immunoreactivity and a method for the production thereof |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276497A2 Mixture of defibrotide and g-csf and its use for activating haematopoietic progenitors |
| 01/22/2003 | EP1276483A2 Compositions and methods for treating amyloidosis using sulphonate derivatives |
| 01/22/2003 | EP1276463A1 Hemostatic agent, method and carrier for applying a blood clotting agent |
| 01/22/2003 | EP1107980B1 CRYSTALLINE FORMS OF EtO2C-CH2-(R)Cgl-Aze-Pab-OH |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP1084129B1 Cyclic boroproline compounds |
| 01/22/2003 | EP1017405A4 Therapeutic hemoglobin composition having isotropically increased size |
| 01/22/2003 | EP0968174B1 Optically active 2-aminotetraline, process for its preparation and pharmaceutical compositions containing same, active in preventing and treating septic shock |
| 01/22/2003 | CN1392875A Condensed azepines as vasopressino agonists |
| 01/22/2003 | CN1392157A New anti-embolism medicine using small peptide arginine-glycine-aspartic acid (RGD) as leading compound |
| 01/22/2003 | CN1099425C 新的肽衍生物 New peptide derivatives |
| 01/21/2003 | US6509376 Utilization of dialkyfumarates |
| 01/21/2003 | US6509365 Useful as inhibitors of poly(ADP-ribose)polymerase and for the production of drugs. |
| 01/21/2003 | US6509364 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2α antagonists |
| 01/21/2003 | US6509363 P38 is a mitogen-activated protein kinase; pyrrole, oxazole, thiazole, and imidazole derivatives |
| 01/21/2003 | US6509351 A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation |
| 01/21/2003 | US6509346 Chemokine receptor antagonists and methods of use therefor |
| 01/21/2003 | US6509335 This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of |
| 01/21/2003 | US6509165 Detecting the ability of proinsulin peptide to preferentially stimulate the T-cells of diabetic subjects by measuring the ability of the T-cells to proliferate or ability of the T-cells to produce cytokines |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/21/2003 | CA1341416C Hirudine variants, their use and preparation process |
| 01/17/2003 | WO2002006269A1 Cyclic amino acid derivatives |
| 01/17/2003 | CA2415964A1 Cyclic amino acid derivatives |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004503A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | WO2003004498A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 01/16/2003 | WO2003004497A1 Novel heterocyclic compound |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004487A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | WO2003004473A1 Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2003004454A1 Linked cyclitols and their polysulfated derivatives |
| 01/16/2003 | WO2003004027A1 Substituted anilinic piperidines as mch selective antagonists |
| 01/16/2003 | WO2003004022A1 Aryl (or heteroaryl) azolylcarbynol derivatives for the treatment of urinary incontinence |
| 01/16/2003 | WO2003004019A1 Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia |
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2003003975A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | WO2002077023A3 A new essential downstream component of the wingless signalling pathway |
| 01/16/2003 | WO2002072527A3 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 01/16/2003 | WO2002050034A3 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 01/16/2003 | WO2002043859A3 Cartridges useful in cleaning dialysis solutions |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002040016A3 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | WO2002010406A3 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | US20030013745 Urazole compounds useful as anti-inflammatory agents |
| 01/16/2003 | US20030013732 Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| 01/16/2003 | US20030013728 Inhibitors of thrombin induced platelet aggregation |
| 01/16/2003 | US20030013713 Compounds as PDE IV and TNF-inhibitors |
| 01/16/2003 | US20030013704 Adamantane derivatives |
| 01/16/2003 | US20030013697 Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal |
| 01/16/2003 | US20030013691 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012778 Reversibly inactivated acidified plasmin |
| 01/16/2003 | CA2454613A1 Substituted anilinic piperidines as mch selective antagonists |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452646A1 Derivatives of aryl(or heteroaryl) azolylcarbinols for the treatement ofurinary incontinence |